Долгая жизнь с муковисцидозом. Коллектив авторов
Soc Med 2009; 102(Suppl 1): 49–53.
189
Elphick HE, Southern KW. Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst Rev 2012; 6: CD002204.
190
Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37(Suppfl3):S225-64.
191
Hennig S, Waterhouse TH, Bell SC, et al. A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. Br J Clin Pharmacol 2007; 63: 438-50.
192
Bruggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009; 48: 1441-58.
193
Bruggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009; 48: 1441-58.
194
Tanou K, Zintzaras E, Kaditis AG. Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: a synthesis of published evidence. Pediatr Pulmonol 2014; 49: 503-7.
195
Jat KR, Walia DK, Khairwa A. Anti-lgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst Rev 2013; 9:CD010288.
196
Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. New Engl J Med 1996; 335: 179-88.
197
Hayes D Jr, Higgins RS, Kirkby S, et al. Impact of pulmonary hypertension on survival in patients with cystic fibrosis undergoing lung transplantation: an analysis of the UNOS registry. J Cyst Fibros 2014; 13: 416-23.
198
Toneili AR. Pulmonary hypertension survival effects and treatment options in cystic fibrosis. Curr Opin Pulm Med 2013; 19: 652-61.
199
Elphick HE, Mallory G. Oxygen therapy for cystic fibrosis. Cochrane Database Syst Rev 2013; 7: CD003884.
200
Elphick HE, Mallory G. Oxygen therapy for cystic fibrosis. Cochrane Database Syst Rev 2013; 7: CD003884.
201
Elphick HE, Mallory G. Oxygen therapy for cystic fibrosis. Cochrane Database Syst Rev 2013; 7: CD003884.
202
Fauroux B. Why, when and how to propose noninvasive ventilation in cystic fibrosis? Minerva Anesthesio 2011; 77: 1108-14.
203
Fauroux B. Why, when and how to propose noninvasive ventilation in cystic fibrosis? Minerva Anesthesio 2011; 77: 1108-14.
204
Young AC, Wilson JW, Kotsimbos TC, et al. Randomised placebo controlled trial of non-invasive ventilation for hypercapnia in cystic fibrosis. Thorax 2008; 63: 72-7.
205
Fauroux B. Why, when and how to propose noninvasive ventilation in cystic fibrosis? Minerva Anesthesio 2011; 77: 1108-14.
206
Flight WG, Shaw J, Johnson S, et al. Long-term non-invasive ventilation in cystic fibrosis – experience over two decades. J Cyst Fibros 2012; 11: 187-92.
207
Young AC, Wilson JW, Kotsimbos TC, et al. Randomised placebo controlled trial of non-invasive ventilation for hypercapnia in cystic fibrosis. Thorax 2008; 63: 72-7.
208
Mehta S, Hill NS. Noninvasive ventilation. Am J Respir Crit Care Med 2001; 163: 540-77.
209
Efrati O, Bylin I, Segal E, et al. Outcome of patients with cystic fibrosis admitted to the intensive care unit: is invasive mechanical ventilation a risk factor for death in patients waiting lung transplantation? Heart Lung 2010; 39: 153-9.
210
Jones A, Bilton D, Evans TW, et al. Predictors of outcome in patients with cystic fibrosis requiring endotracheal intubation. Respirology 2013; 18: 630-6.
211
Nosotti M, Rosso L, Tosi D, et al. Extracorporeal membrane oxygenation with spontaneous breathing as a bridge to lung transplantation. Interact CardiovasoThorac Surg 2013; 16:55-9.
212
Fuehner T, Kuehn C, Hadem J, etal. Extracorporeal membrane oxygenation in awake patients as bridge to lung transplantation. Am J Respir Crit Care Med 2012; 185: 763-8.
213
Szaff M, Høiby N. Antibiotic treatment of Staphylococcus aureus infection in cystic fibrosis. Acta Paediatr Scand 1982; 71: 821–6.
214
Hoiby N. Cystic fibrosis: infection. Schweiz Med Wochenschr 1991; 121:105-9.
215
Andersen DH. Therapy and prognosis of fibrocystic disease of the pancreas. Pediatrics 1949; 3: 406-17.
216
Høiby N. Epidemiological investigations of the respiratory tract bacteriology in patients with cystic fibrosis. Acta Pathol Microbiol Scand В Microbiol Immunol 1974; 82: 541-50.
217
Spencer RC. The emergence of epidemic, multiple-antibiotic-resistant Stenotrophomonas (Xanthomonas) maltophilia and Burkholderia (Pseudomonas) cepacia. J Hosp Infect 1995; 30(Suppl): 453-64.
218
Lipuma JJ. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev 2010; 23: 299–323.
219
Hauser AR, Jain M, Bar-Meir M, et al. Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin Microbiol Rev 2011; 24: 29–70.
220
Courtney JM, Bradley J, Mccaughan J, et al. Predictors of mortality in adults with cystic fibrosis. Pediatr Pulmonol 2007; 42: 525-32.
221
Courtney JM, Dunbar KE, McDowell A, et al. Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults. J Cyst Fibros 2004; 3: 93-8.
222
Courtney JM, Dunbar KE, McDowell A, et al. Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults. J Cyst Fibros 2004; 3: 93-8.
223
Isles A, Maclusky I, Corey M, et al. Pseudomonas cepacia infection